Insider Buying: Achieve Life Sciences, Inc. (NASDAQ:ACHV) CFO Buys 10,000 Shares of Stock

Achieve Life Sciences, Inc. (NASDAQ:ACHV) CFO Mark K. Oki bought 10,000 shares of the company’s stock in a transaction on Monday, March 17th. The stock was bought at an average cost of $2.89 per share, with a total value of $28,900.00. Following the completion of the purchase, the chief financial officer now owns 10,000 shares of the company’s stock, valued at approximately $28,900. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Achieve Life Sciences Trading Up 2.2 %

Shares of NASDAQ ACHV opened at $2.81 on Friday. Achieve Life Sciences, Inc. has a 1-year low of $2.51 and a 1-year high of $5.59. The company has a market cap of $97.46 million, a PE ratio of -2.49 and a beta of 1.67. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31. The company has a 50-day moving average of $3.09 and a two-hundred day moving average of $3.95.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.06). As a group, equities analysts expect that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Achieve Life Sciences

Institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC grew its position in shares of Achieve Life Sciences by 185.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,545 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 4,905 shares during the period. Sigma Planning Corp acquired a new stake in shares of Achieve Life Sciences during the 4th quarter worth approximately $37,000. ADAR1 Capital Management LLC grew its position in shares of Achieve Life Sciences by 14,375.8% during the 4th quarter. ADAR1 Capital Management LLC now owns 13,173 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 13,082 shares during the period. SBI Securities Co. Ltd. acquired a new stake in shares of Achieve Life Sciences during the 4th quarter worth approximately $49,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Achieve Life Sciences during the 4th quarter worth approximately $58,000. Institutional investors and hedge funds own 33.52% of the company’s stock.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.